Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veraxa Biotech Holding AGVRXA -10.66%6 3-Year RORE % is 0.00 as of Dec. 2025. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,290 Biotechnology companies, Veraxa Biotech Holding AG ranks worse than 77519.3% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Veraxa Biotech Holding AG does not have enough data to calculate 3-Year RORE %.
Veraxa Biotech Holding AG (NAS:VRXA) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Veraxa Biotech Holding AG 3-Year RORE % Related Terms
Veraxa Biotech Holding AG 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG 3-Year RORE % Chart
Veraxa Biotech Holding AG Annual Data
Trend
Dec23
Dec24
Dec25
3-Year RORE %
0.00
0.00
0.00
Veraxa Biotech Holding AG Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
3-Year RORE %
0.00
0.00
0.00
0.00
0.00
VRXA vs TTRX, IRD, IFRX: 3-Year RORE % Comparison
For the Biotechnology subindustry, Veraxa Biotech Holding AG's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veraxa Biotech Holding AG 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Veraxa Biotech Holding AG's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Veraxa Biotech Holding AG (VRXA) has a 3-Year RORE % of 0.00 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Veraxa Biotech Holding AG and its competitors. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 1290 companies in the Biotechnology industry.
Is Veraxa Biotech Holding AG's 3-Year RORE % too high?
Veraxa Biotech Holding AG's current 3-Year RORE % is 0.00. Based on the distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 1290 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's 3-Year RORE % compare to TTRX and IRD?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #999999 out of 1290 companies for 3-Year RORE %. This places Veraxa Biotech Holding AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current 3-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current 3-Year RORE % of 0.00. The current 3-Year RORE % is 0.00. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current 3-Year RORE % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score
Get the complete analysis for VRXA
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRXA has been successfully added to your 
